Autor : Palmero, Domingo J. 1
1IFull Professor of Pulmonology, UBA (University of Buenos Aires). Director of the Instituto Vaccarezza, UBA, Chief of the Pulmonology and Tisiology Unit, Hospital Muñiz
https://doi.org/10.56538/ramr.XSTI8345
Correspondencia : Domingo J. Palmero. E-mail: djpalmero@intramed.net
The “End TB Strategy”, published
by the World Health Organization (WHO) in 2015, aims to reduce the number of
deaths from tuberculosis (TB) by 95 %, the incidence by 90 %, and catastrophic
expenses related to the disease to 0 % by 2035.1 2035 being 11 years from now,
we don’t see great optimism in the achievement of these objectives. One of the
reasons why TB is still a global pandemic is its prolonged treatment and the
challenges to achieving proper adherence to it. Adherence to prolonged treatments,
including TB, is a complex and dynamic phenomenon in which a wide range of
factors influences the behavior of treatment acceptance. The WHO defines
adherence as: “the degree to which a patient’s behavior, in terms of
medicine-taking, following a diet, or making lifestyle changes, corresponds
with the recommendations of the healthcare provider.”2
Adherence encompasses various
behaviors, including: 1) spreading and maintaining a treatment program; 2)
attending follow-up appointments; 3) using prescribed medication properly; 4)
making appropriate changes in lifestyle; 5) avoiding contraindicated
behaviors. According to the WHO, there are five interacting factors that
influence treatment adherence: 1) Socioeconomic factors (poverty, access to
healthcare and medications, illiteracy, the presence of effective social
support networks, and cultural adaptation to health practices); 2)
Treatment-related factors (complexity and duration of the prescribed regimen,
past therapeutic failures, and adverse effects); 3) Patient-related factors
(lack of resources, religious beliefs, educational level, lack of perception of
improvement regarding the disease, trust in the physician, desire to feel in
control, self-efficacy, and mental health); 4) Disease-related factors, such as
its severity and impact on the patient’s mental state; and 5) Factors related
to the healthcare system and team (health facilities with inadequate
infrastructure and deficient resources, underpaid and overworked healthcare
personnel that provide brief, low-quality consultations, inadequately trained
healthcare staff, limited system capacity to educate patients and provide
follow-up in chronic diseases, and lack of knowledge about adherence and how to
improve it).3,4
In Argentina, Arrossi
et al conducted a cross-sectional study where they identified poverty and the
fact of receiving healthcare in hospitals instead of nearby health centers as
factors that are significantly related to non-adherence.5
A case-control study in Peru
described male gender, adverse reactions, history of non-compliance with
treatment, poverty, and the use of illicit drugs as adverse factors for
adherence. Conversely, adequate TB knowledge and easy access to a healthcare
center during regular hours were factors that improved adherence.6
In this issue of the American
Review of Respiratory Medicine (RAMR), Jajati et al7 published an original study
for Argentina on the direct costs of the treatment of pulmonary tuberculosis in
adherent and non-adherent patients at a public hospital of the city of Buenos
Aires. In their study, they compare the costs associated with a) an adherent
outpatient with b) adherent inpatients, and c) non-adherent inpatients. The
costs in USD were: 257.79; 4,015.26, and 8,165.87, respectively. In other
words, the direct costs of treating an outpatient were approximately 15 times
lower than those of hospitalized patients. Furthermore, a non-adherent
inpatient incurred double the cost of an adherent inpatient. They mention
smoking, homelessness (extreme poverty), malnutrition, alcoholism, substance
abuse, and HIV as statistically significant factors for non-adherence.
Several international studies
cited by Jajati et al reach to the same conclusion:
non-adherence has both economic and health costs. This is because patients who
remain infectious due to incomplete treatment become sources of disease spread.
Moreover, there is a risk of selecting drug-resistant mutants and creating and
spreading drug-resistant strains of Mycobacterium tuberculosis.
Management and control strategies
for TB have shown to be vulnerable and insufficient during the COVID-19
pandemic. Isolation, social distancing, and the collapse of the healthcare
system have limited patient access to healthcare facilities, worsening the TB
situation in the countries and hindering proper adherence.8
Particularly in Argentina and
especially in the AMBA (Buenos Aires Metropolitan Area), the worsening of
socio-economic conditions is another significant factor negatively impacting
patient adherence to treatment. At the hospital level there are patients with
very low incomes, overwhelmed by the daily challenges of securing food, having
shelter, transportation, dealing with crime, and coping with addictions, among
other unfortunate factors. Within the bleak environment in which these
individuals live, chronic cough seems like a minor concern, and they often seek
healthcare with extremely critical TB. Unfortunately, under these
circumstances, we witness the death of young individuals from TB, a disease
that can be prevented, easily diagnosed and treated effectively. If they manage
to recover, once they are discharged, they return to their complex life
situations, and regrettably, it is common for them to discontinue their
treatment.
Is there any possibility of
improving adherence? Yes. Directly Observed Therapy (DOT) is a tool that has
been applied for several years with varying levels of success. An important
aspect is that it should be carried out in the vicinity of the patient’s
residence or shelter (in the case of the homeless). Digital technology helps.
The Video Observed Therapy (VOT) and its variants, through a mobile phone, have
shown to be more effective than DOT.9,10
Well, let’s assume an ideal
scenario where we have an efficient healthcare system that is also concerned
about TB. Would we be able to achieve near 100 % adherence, so that TB would
have to decrease until it disappears?
Let’s look at the example of a
bacterial disease that can be easily diagnosed, needs short treatment, and has
no drug resistance: syphilis.
With such a promising picture,
has it disappeared? NO. In the United States, syphilis rates are at their
highest point in 70 years. The Centers for Disease Control and Prevention (CDC)
in the United States indicated that 207,255 cases were reported in 2022, which
represent a significant increase in five years.11
So, what are we missing in our
analysis?: the human factor, both from the healthcare
system and the patients. Could we modify the healthcare system to make it more
“friendly” towards those who need its services? Quick, warm,
efficient, understanding care, without extremely long wait times or bureaucracy
that can be incomprehensible to many patients. Maybe we could, but it
will take a long time, considerable efforts, and, above all, interest in making
this transformation.
And with regard to the patients,
could we make them understand the illness they are experiencing and the need
for treatment? We could achieve that with an educational effort, in most
patients, but there will always be a difficult-to-reach remainder with seemingly
insurmountable barriers, that will unfortunately carry their TB to the ultimate
consequences (for them and the surrounding society).
I don’t want to conclude this
editorial with such a pessimistic view of the future of TB. Let’s remember the
“golden” 80 % (for example, in vaccination). If we can ensure that a similar
or higher percentage of TB patients can be integrated into a comprehensive and
sustainable healthcare system, providing them with adequate social and economic
support, perhaps we will see a significant decrease in the incidence and
prevalence of TB over time. Hopefully!
REFERENCES
1. Uplekar
M, Weil D, Lonnroth K, et al. WHO’s new end TB
strategy. Lancet. 2015;85:1799-801.
https://doi.org/10.1016/S0140-6736(15)60570-0
2.
Organización Panamericana de la Salud. Adherencia a los tratamientos a largo
plazo. Pruebas para la acción. 2004. En:
https://iris.paho.org/handle/10665.2/41182
3.
Ortega Cerda JJ, Sánchez Herrera D, Rodríguez Miranda OA, Ortega Legaspi JM. Adherencia terapéutica: un problema de atención
médica. Acta Méd Grupo Ángeles. 2018;6(3). Disponible en: https://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1870-72032018000300226
4. Munro SA, Lewin
SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient Adherence to Tuberculosis Treatment: A
Systematic Review of Qualitative Research. PLoS Med.
2007;4(7):e238. https://doi.org/10.1371/journal.pmed.0040238
5. Arrossi
S, Herrero MB, Greco A, Ramos S. Predictive factors
of non-adherence to tuberculosis treatment in the metropolitan area of Buenos
Aires, Argentina. Salud colectiva. 2012;8(Suppl 1):S65-S76.
https://doi.org/10.18294/sc.2012.866
6. Culqui
DR, Munayco CV, Grijalva
CG, et al. Factors Associated With the Non-completion of Conventional
Anti-Tuberculosis Treatment in Peru. Arch Bronconeumol.
2012;48:150-5. https://doi.org/10.1016/j.arbres.2011.12.008
7.
Jajati M, Sívori, M,
Capelli L, y cols. Costos directos del tratamiento de la tuberculosis pulmonar
en pacientes adherentes y no adherentes en un hospital público de la Ciudad de
Buenos Aires. Rev Am Med Resp. 2024;24:22-31.
https://doi.org/10.56538/ramr.LKZF6121.
8. Wang X, He W, Lei J, et al.
Impact of COVID-19 pandemic on pre-treatment delays, detection, and clinical
characteristics of tuberculosis patients in Ningxia Hui
autonomous region, China. Front Public Health. 2021;9:644536.
https://doi.org/10.3389/fpubh.2021.644536
9. Pradipta
IS, Houtsma D, van Boven
JFM, et al. Interventions to improve medication adherence in tuberculosis
patients: a systematic review of randomized controlled studies. Prim Care Respir Med. 2020;30:21.
https://doi.org/10.1038/s41533-020-0179-x
10. Nisha
KJ, Vaz C, Chai PR, Rodrigues R. The Acceptability of
Adherence Support via Mobile Phones for Antituberculosis
Treatment in South India: Exploratory Study. JMIR Form Res. 2022;6(5):e37124. https://doi.org/10.2196/37124
11. Nelson R. Syphilis rates soar
in the USA amid penicillin shortage. The Lancet.
2023;402(10401):515. https://doi.org/10.1016/S0140-6736(23)01665-3